文献速递心律失常血脂与心血管预防

房颤患者接受非推荐剂量直接口服抗凝药的全因死亡率分析

Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants.
PubMed 文献 · J Am Coll Cardiol · 2020-01-01

基于GARFIELD-AF前瞻性注册研究(2013–2016年入组34,926例,其中10,426例接受DOAC),评估新诊断房颤患者DOAC剂量与推荐指南的一致性对2年全因死亡、卒中/SE及大出血的影响。结果显示72.9%患者使用推荐剂量,23.2%剂量不足,3.8%剂量过量;非推荐剂量(剂量不足与过量合并)较推荐剂量与更高的全因死亡风险相关(HR 1.24,95%CI 1.04–1.48)。

要点

  • 多数新诊断房颤患者(72.9%)接受推荐剂量DOAC,23.2%剂量不足,3.8%剂量过量。
  • 非推荐剂量(尤其剂量不足)与全因死亡风险升高相关,超额死亡为心血管性。
  • 卒中/SE及大出血风险在不同剂量水平间无显著差异。

核心结论

  • 在GARFIELD-AF注册研究中,非推荐剂量DOAC处方的房颤患者较推荐剂量者全因死亡风险更高,多为心血管死亡,校正基线因素后仍显著。

研究设计与样本

  • 前瞻性观察性注册研究GARFIELD-AF(NCT01090362),2013至2016年入组34,926例新诊断房颤患者,其中10,426例接受DOAC,随访2年。

主要发现

  • 72.9%患者接受推荐剂量,23.2%剂量不足,3.8%剂量过量。
  • 非推荐剂量(剂量不足与过量合并)对比推荐剂量,全因死亡HR 1.24(95%CI 1.04–1.48);剂量不足HR 1.25(95%CI 1.04–1.50);剂量过量HR 1.19(95%CI 0.83–1.71)。
  • 超额死亡为心血管性,包括心力衰竭和心肌梗死。
  • 卒中/SE和主要出血风险在不同剂量水平间无显著差异;剂量不足患者出血风险显著更低。
  • 剂量过量患者卒中/SE(HR 1.51,95%CI 0.79–2.91)和主要出血(HR 1.29,95%CI 0.59–2.78)风险呈非显著升高趋势。

临床怎么用

  • 处方DOAC时应严格依据当地指南推荐剂量,避免剂量不足或过量,以降低死亡风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The recommended doses for direct oral anticoagulants (DOACs) to prevent stroke and systemic embolism (SE) in patients with atrial fibrillation (AF) are described in specific regulatory authority approvals. OBJECTIVES: The impact of DOAC dosing, according to the recommended guidance on all-cause mortality, stroke/SE, and major bleeding, was assessed at 2-year follow-up in patients with newly diagnosed AF. METHODS: Of a total of 34,926 patients enrolled (2013 to 2016) in the prospective GARFIELD-AF (Global Anticoagulant Registry in the FIELD-AF), 10,426 patients received a DOAC. RESULTS: The majority of patients (72.9%) received recommended dosing, 23.2% were underdosed, and 3.8% were overdosed. Nonrecommended dosing (underdosage and overdosage combined) compared with recommended dosing was associated with a higher risk of all-cause mortality (hazard ratio [HR]: 1.24; 95% confidence interval [CI]: 1.04 to 1.48); HR: 1.25 (95% CI: 1.04 to 1.50) for underdosing, and HR: 1.19 (95% CI: 0.83 to 1.71) for overdosing. The excess deaths were cardiovascular including heart failure and myocardial infarction. The risks of stroke/SE and major bleeding were not significantly different irrespective of the level of dosing, although underdosed patients had a significantly lower risk of bleeding. A nonsignificant trend to higher risks of stroke/SE (HR: 1.51; 95% CI: 0.79 to 2.91) and major bleeding (HR: 1.29; 95% CI: 0.59 to 2.78) was observed in patients with overdosing. CONCLUSIONS: In GARFIELD-AF, most patients received the recommended DOAC doses according to country-specific guidelines. Prescription of nonrecommended doses was associated with an increased risk of death, mostly cardiovascular death, compared with patients on recommended doses, after adjusting for baseline factors. (Global Anticoagulant Registry in the Field-AF [GARFIELD-AF]; NCT01090362).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Camm AJ, Cools F, Virdone S, et al. Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants. J Am Coll Cardiol. 2020. PMID: 32943160. doi:10.1016/j.jacc.2020.07.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。